Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center


Ball - Ambassadors

Sydney Ball
Sydney Ball

I joined the Vanderbilt-Ingram Cancer Center Ambassadors in 2017 through the Young Leaders Council Leadership Program. The VICC Ambassadors are an amazing group of passionate individuals that I am thankful to have the opportunity to partner alongside in the fight against cancer. Our experience together has been incredible; the influence we have made has been significant; and the friendships we have formed have been endearing.

I think everyone has been impacted, at some level, by cancer. However, cancer had a dramatic impact on my life in 2016 when my grandfather lost his fight to lung cancer and my cousin died of an undiagnosed metastatic cancer. Being able to raise awareness about cancer research through the VICC Ambassadors has been a meaningful way for me to give back to the community, while also awarding discovery grants for a cause that has closely impacted my family.

As part of the VICC Ambassadors, you will have the opportunity to be educated on trends in medical research, vote on where the research dollars are distributed, and help raise awareness for innovative philanthropic efforts. We look forward to you partnering with us on this journey and hope you will participate in any way that you can!


SMART Precision Cancer Medicine

A diagnosis of cancer is a life-changing event whi

Hertha - Ambassadors

Erin Hertha
Erin Hertha

The mission to find a cure for cancer is something I strongly believe in and value. Most of us have our own stories about how cancer has affected someone we loved dearly. My story is about my mother, who was diagnosed with lung cancer in 2001. At the time, we lived in a small city where there was not a powerful resource like Vanderbilt-Ingram Cancer Center. The doctors tried to do what they could, but her advanced cancer was past the point of intervention. My mother lost her battle on November 10, 2001, two months after my 13th birthday. Cancer left a void in my heart by taking one of the people I loved most in the world.  

Eighteen years later, my path led me to Vanderbilt-Ingram Cancer Center where I work under the incredible leadership of Jennifer Pietenpol, PhD. The work, passion and devotion I witness daily from Dr. Pietenpol, leadership and staff in Vanderbilt-Ingram show me why we are the leader in prevention, diagnosis and treatment of cancer. 

I joined VICC Ambassadors because of my passion for finding cures and my belief in this program. My story may not have had the ending I hoped for, but I am optimistic that the VICC Ambassadors can help make great strides toward giving others better endings to their stories.
 


SEL24 / MEN1703 in Patients With Acute Myeloid Leukemia

Leukemia

The purpose of the clinical trial is to identify the highest dose of SEL24 / MEN1703 drug with acceptable safety profile and that can be used in patients with Acute Myeloid Leukemia.
Leukemia
I/II
Strickland, Stephen
NCT03008187
VICCHEM16123

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-803 / M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, gemcitabine, and cisplatin to determine the safety and maximum tolerated dose.
Not Available
I
Not Available
NCT02278250
VICCPHI14126

Nivolumab and Ipilimumab in Estimating Anti-Tumor Activity and Identifying Potential Predictors of Response in Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery

Melanoma

This phase II trial studies how well nivolumab and ipilimumab work in estimating anti-tumor activity and identifying potential predictors of response in patients with melanoma that is spreading to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Melanoma
N/A
Johnson, Douglas
NCT02978443
VICCMEL1816

Ibrutinib in Treating Patients with Refractory or Relapsed Lymphoma after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Leukemia, Lymphoma
II
Jagasia, Madan
NCT02869633
VICCBMT1651

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

Lung

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
II
Horn, Leora
NCT02864992
VICCTHO1691

Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may work better in treating patients with breast cancer.
Not Available
II
Mayer, Ingrid
NCT02860000
VICCBRE1846

Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

This phase I / II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with pancreatic neuroendocrine tumors (PNET) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) and cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be a better treatment for patients with PNET.
Not Available
I/II
Not Available
NCT01465659
VICCGI1250

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: